Follow
Lisa Johnson
Lisa Johnson
Verified email at gilead.com - Homepage
Title
Cited by
Cited by
Year
The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion
C Haluszczak, AD Akue, SE Hamilton, LDS Johnson, L Pujanauski, ...
Journal of Experimental Medicine 206 (2), 435-448, 2009
4382009
TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding
PS Petrova, NN Viller, M Wong, X Pang, GHY Lin, K Dodge, V Chai, ...
Clinical cancer research 23 (4), 1068-1079, 2017
2572017
Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies
SM Ansell, MB Maris, AM Lesokhin, RW Chen, IW Flinn, A Sawas, ...
Clinical Cancer Research 27 (8), 2190-2199, 2021
1342021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
OO Oluwole, K Bouabdallah, J Muñoz, S De Guibert, JM Vose, NL Bartlett, ...
British journal of haematology 194 (4), 690-700, 2021
1032021
Targeting CD47 in Sézary syndrome with SIRPαFc
LDS Johnson, S Banerjee, O Kruglov, NN Viller, SM Horwitz, A Lesokhin, ...
Blood advances 3 (7), 1145-1153, 2019
872019
A chronic need for IL-21
LDS Johnson, SC Jameson
Science 324 (5934), 1525-1526, 2009
532009
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets
GHY Lin, V Chai, V Lee, K Dodge, T Truong, M Wong, LD Johnson, ...
PloS one 12 (10), e0187262, 2017
502017
Quantification of a Proteotypic Peptide from Protein C Inhibitor by Liquid Chromatography–Free SISCAPA-MALDI Mass Spectrometry: Application to Identification of Recurrence of …
M Razavi, LDS Johnson, JJ Lum, G Kruppa, NL Anderson, TW Pearson
Clinical chemistry 59 (10), 1514-1522, 2013
502013
Histidine Rich Glycoprotein and Cancer: A Multi-faceted Relationship
LDS Johnson, HA Goubran, RR Kotb
Anticancer Research 34 (2), 593-603, 2014
432014
A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies
S Ansell, RW Chen, IW Flinn, MB Maris, OA O'Connor, LDS Johnson, ...
Blood 128 (22), 1812, 2016
402016
Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines
E Tran, JS Nielsen, DA Wick, AV Ng, LDS Johnson, NJ Nesslinger, ...
PLoS One 5 (12), e15625, 2010
362010
TGF-β sensitivity restrains CD8+ T cell homeostatic proliferation by enforcing sensitivity to IL-7 and IL-15
LDS Johnson, SC Jameson
Public Library of Science 7 (8), e42268, 2012
292012
A single direct intratumoral injection of TTI-621 (SIRPαFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Preliminary …
C Querfeld, J Thompson, M Taylor, R Pillai, LDS Johnson, T Catalano, ...
Blood 130, 4076, 2017
282017
Negative regulators in homeostasis of naive peripheral T cells
JF Modiano, LDS Johnson, D Bellgrau
Immunologic research 41, 137-153, 2008
282008
Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy
R Uger, L Johnson
Expert Opinion on Biological Therapy 20 (1), 5-8, 2020
272020
Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation
LDS Johnson, SC Jameson
The Journal of Immunology 184 (10), 5604-5611, 2010
212010
TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies …
GHY Lin, NN Viller, M Chabonneau, L Brinen, T Mutukura, K Dodge, ...
Cancer Research 78 (13_Supplement), 2709-2709, 2018
122018
TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 “do not eat” signal, induces objective responses in patients with advanced, relapsed/refractory diffuse …
SM Ansell, IW Flinn, MB Maris, OA O'Connor, A Lesokhin, AS Advani, ...
Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 4116 …, 2017
122017
Intralesional administration of the CD47 antagonist TTI-621 (SIRPαFc) induces responses in both injected and non-injected lesions in patients with relapsed/refractory mycosis …
C Querfeld, J Thompson, MH Taylor, R Pillai, LDS Johnson, T Catalano, ...
Blood 132, 1653, 2018
102018
Intralesional injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and …
C Querfeld, JA Thompson, M Taylor, R Pillai, LDS Johnson, T Catalano, ...
European Journal of Cancer 101, S34, 2018
102018
The system can't perform the operation now. Try again later.
Articles 1–20